Cantor Fitzgerald Weighs in on BCAX FY2025 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Bicara Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings of ($2.50) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

A number of other analysts have also commented on BCAX. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Stifel Nicolaus started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target on the stock. TD Cowen started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating for the company. HC Wainwright initiated coverage on Bicara Therapeutics in a report on Friday, December 6th. They set a “buy” rating and a $42.00 target price on the stock. Finally, Rodman & Renshaw began coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $43.00.

Bicara Therapeutics Trading Up 0.4 %

NASDAQ BCAX opened at $11.97 on Thursday. Bicara Therapeutics has a 52 week low of $11.51 and a 52 week high of $28.09. The company has a 50 day moving average price of $17.46.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14).

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors have recently bought and sold shares of the business. First Turn Management LLC bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $14,324,000. Geode Capital Management LLC bought a new position in Bicara Therapeutics during the third quarter worth $1,239,000. Vestal Point Capital LP acquired a new position in shares of Bicara Therapeutics in the third quarter valued at $10,825,000. FMR LLC bought a new position in shares of Bicara Therapeutics in the third quarter valued at about $57,913,000. Finally, Braidwell LP acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter worth about $42,219,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.